Longeveron(US:LGVN) Globenewswire·2025-11-19 14:15Core Insights - Longeveron Inc. has announced the selection of its submission on laromestrocel for a poster presentation at the 18th Clinical Trials on Alzheimer's Disease Conference, highlighting its potential in treating Alzheimer's disease [1][2] Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with its lead product being laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell therapy [4] - The company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and Pediatric Dilated Cardiomyopathy (DCM) [4] - Laromestrocel has received five important FDA designations, including Orphan Drug designation and Fast Track designation for HLHS, and Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease [4] Product Information - Laromestrocel is derived from mesenchymal stem cells (MSCs) isolated from the bone marrow of young healthy adult donors, which are believed to have multiple mechanisms of action that may lead to anti-inflammatory and regenerative responses [3][4] - The product is designed to address a range of rare and aging-related diseases, leveraging the body's endogenous biological repair mechanisms [3][4] Event Details - The poster presentation will take place on December 1-2, 2025, at the CTAD 2025 conference, focusing on the results from the CLEAR MIND study regarding reduced brain neuroinflammation after laromestrocel treatment in mild Alzheimer's disease [2]